The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte has reached a new clinical milestone in arteriovenous (AV) access for dialysis, unveiling interim Phase 3 (V012) results focused on female patients.
The ATEV product achieved the primary endpoint of the V012 study, delivering statistically significant superiority in catheter-free days with a p-value of 0.00070 compared to autologous arteriovenous options. This milestone supports the potential of Humacyte’s bioengineered vessel for improving outcomes in dialysis access, particularly among female patients.
View post on X Loading...
Humacyte previously announced plans to present interim results from a women-only vascular access study at a specialized forum in June 2026. The company also introduced its Symvess acellular tissue engineered vessels during a hands-on simulation event at VAM TOUCHPOINT, according to a recent demonstration. These developments form part of Humacyte’s ongoing clinical and product initiatives in vascular access.